Condoms sometimes permissible to stop AIDS: Pope
VATICAN CITY (Reuters) - Using condoms may sometimes be justified to stop the spread of AIDS, Pope B ...
World health officials take aim at tobacco additives
PUNTA DEL ESTE, Uruguay (Reuters) - World health officials recommended on Saturday limiting additive ...
Nighttime delivery linked to brain problems
NEW YORK (Reuters Health) - Babies born late at night or in the wee hours of the morning may have a ...
Date published: Sun, 21 Nov 2010 11:55:20 -0500
Reimbursement Notes: UnitedHealthcare Tightens Coverage Policy for Bevacizumab
No abstract available
Pathway or Pathways? Major Pennsylvania Insurer Takes a Stand, But Now a Long-Time Partnership Has Turned Difficult
Speak Up: The Moment that Changed How I Talk to My Patients
Date published: Sun, 21 Nov 2010 10:43:24 -0600
NEW PATIENT FORMSResourcesPrivacy NoticeSatisfaction Survey
*LAUNCHING* Phase I Clinical Trials Program at Gabrail Cancer Center
The clinical trial and new drug development program at Gabrail Cancer Center has recently reached a new milestone towards its goal of bringing cutting-edge cancer technology to our community. With a sense of pride and zeal for higher achievements, I am personally informing you that we have recently launched our Phase I clinical trials program.
Phase I clinical trials are the most sophisticated and complex initial steps in new drug development. This process involves the first step in testing potential anti-cancer drugs after animal experimentation is completed.
Research centers chosen to conduct Phase I clinical trials in their own designated Phase I unit must demonstrate a plethora of characteristics including utmost accuracy, clinical competency, well-trained dedicated staff, and state-of-the-art facility and equipment necessary to store and reconstitute the experimental agents under strictly-controlled conditions. ... click to continue
Specializing in the diagnosis and treatment of cancer and blood diseases.
GCCs services and locations cover northeast, southeast and central Ohio. Services include, medical oncology, hematology, infusion therapy, diagnostics and clinical research. Read more >>>
Gabrail Cancer Center Specialties and Areas of Interest
Phase 1 Clinical Trials
Cancer Pain is one of the most significant complaints amongst cancer patients. At Gabrail Cancer Center we incorporate the latest advances in evaluation and treatment to offer you a long-lasting solution to these problems. Call GCC at 330-492-3345 x 208 to schedule an evaluation for your cancer pain and possible enrollment in one of our clincal trials.
Diagnose cancer early through screening and early detection.
The Family Cancer Registry (FCR) was formed for patients and families to learn about the possible genetically inherited risk of cancer. Physicians analyze the family tree, looking for a specific pattern to determine if there is indeed a genetic predisposition to develop cancer. Formal genetic testing is done when deemed necessary. Family members are counseled about methods of prevention and early detection or even prophylactic surgery procedures. To schedule an appointment call 330-492-3345 x 201.
GABRAIL CANCER CENTER LAUNCHES CLINICAL TRIAL FOR POTENTIAL NEW LUNG CANCER TREATMENT
Good Medicine is Cheaper Medicine Available Now!
ASCO Podcast features Patient Resource Cancer Guide
Mount Union: Physician Assistant Studies Program
CenterWatch Posting of the Breakthrough Cancer Pain Study
AngioChem Presents New Positive Clinical Data on ANG1005 for Brain Cancers at AACR
Lack of Study Volunteers Hobbles Cancer Fight
Gabrail Cancer Center: Small Practice Doing Big Things
Our news can be syndicated by using these rss feeds.
Canton Facility: 4875 Higbee Ave NW, Canton, Ohio 44718
Phone: 330-492-3345 Fax: 330-492-0462
Dover Facility: 115 S. Wooster, Dover, Ohio 44622
Phone: 330-365-2135 Fax: 330-364-9195
Render time: 0.1675 sec, 0.0118 of that for queries. DB queries: 26. Memory Usage: 2,116kb